TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Prescription Omega-3 Fatty Acid Added to Stable Statin Therapy in Patients With Type 2 Diabetes and Hypertriglyceridemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* LDL-C \< 100mg/dL, TG \> 150mg/dL, patients on statin treatment for at least 6 weeks prior to randomization.~* Type 2 Diabetes~* HbA1c ≤ 10.0~Exclusion Criteria:~* Type 1 Diabetes~* Patients with PPAR gamma agonist therapy~* Patients with acute MI, Unstable angina within 6 months~* History of malignant tumor within 2 years~* Women with pregnant, breast-feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Omega-3-acids ethylesters 90 4g, any statin (Type: EXPERIMENTAL): None
- any statin (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PTH and Vibration in OSteoporosis Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Women starting PTH treatment for osteoporosis according to Danish Osteoporosis guidelines~Exclusion Criteria:~* Women currently taking oral glucocorticoids~* Women unable to give informed consent~* Women unable to stand for 2 minutes at a time on the vibration platform~* Women who have contraindications to WBV (e.g. joint prosthesis, pacemakers)

- Gender: FEMALE
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- controlgroup (Type: ACTIVE_COMPARATOR): Teriparatide, 20 microgram/day. 24 months of treatment
- studygroup 1 (Type: EXPERIMENTAL): Teriparatide, 20 microgram/day. 24 months of treatment.~12 months of Whole-body vibration on vibration platforms.
- studygroup 2 (Type: EXPERIMENTAL): Teriparatide, 20 microgram/day. 24 months of treatment.~24 months of Whole-body vibration on vibration platforms

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Delivery of G-Pump™ (Glucagon Infusion) From an OmniPod® to Prevent Hypoglycemia in Post-Bariatric Surgery Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosed with ongoing post-bariatric hypoglycemia with prior episodes of neuroglycopenia, unresponsive to dietary intervention (low glycemic index, controlled carbohydrate portions) and trial of acarbose therapy at the maximally tolerated dose.~* willingness to provide informed consent and follow all study procedures, including attending all scheduled visits.~Exclusion Criteria:~* documented hypoglycemia occurring in the fasting state (\> 12 hours fast);~* chronic kidney disease stage 4 or 5;~* hepatic disease, including serum alanine aminotransferase or aspartate aminotransferase greater than or equal to 3 times the upper limit of normal; hepatic synthetic insufficiency as defined as serum albumin \< 3.0 g/dL; or serum bilirubin \> 2.0;~* congestive heart failure, New York Heart Association class II, III or IV;~* history of myocardial infarction, unstable angina or revascularization within the past 6 months;~* history of a cerebrovascular accident;~* seizure disorder (other than with suspect or documented hypoglycemia);~* active treatment with any diabetes medications except for acarbose;~* active malignancy, except basal cell or squamous cell skin cancers;~* personal or family history of pheochromocytoma or disorder with increased risk of pheochromocytoma (MEN 2, neurofibromatosis, or Von Hippel-Lindau disease);~* known insulinoma;~* major surgical operation within 30 days prior to screening;~* hematocrit ≤ 33%;~* bleeding disorder, treatment with warfarin, or platelet count \<50,000;~* blood donation (1 pint of whole blood) within the past 2 months;~* active alcohol abuse or substance abuse;~* current administration of oral or parenteral corticosteroids;~* pregnancy and/ or Lactation: For women of childbearing potential: there is a requirement for a negative urine pregnancy test and for agreement to use contraception during the study and for at least 1 month after participating in the study.~* use of an investigational drug within 30 days prior to screening.~* there will be no involvement of special vulnerable populations such as pregnant women, prisoners, institutionalized or incarcerated individuals, or others who may be considered vulnerable populations.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- G-Pump™ (glucagon infusion) (Type: EXPERIMENTAL): 0.15 or 0.3 mg G-Pump™ (glucagon infusion) administered from OmniPod® pump

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prevalence Studies After Triple Drug Therapy for Lymphatic Filariasis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 5 years (males and females)~* Able to provide informed consent, or parental/guardian consent for young children, and assent for older children~Exclusion Criteria:~* Unable or unwilling to provide informed consent or (for minors) lacking parental/guardian consent to participate in the study

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 2-Drug Treated Communities (Type: None): Communities who were treated with diethylcarbamazine and albendazole (DA) mass drug administration during the safety study entitled Community Based Safety Study of 2-drug (DA) versus 3-drug (IDA) Therapy for Lymphatic Filariasis.
- 3-Drug Treated Communities (Type: None): Communities who were treated with ivermectin, diethylcarbamazine and albendazole (IDA) mass drug administration during the safety study entitled Community Based Safety Study of 2-drug (DA) versus 3-drug (IDA) Therapy for Lymphatic Filariasis.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients \>=18 years of age;~* histologically documented, locally advanced , recurrent or metastatic NSCLC;~* measurable disease;~* no disease progression after 4 cycles of platinum-based chemotherapy.~Exclusion Criteria:~* unstable systemic disease;~* any other malignancies in the last 5 years.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Erlotinib (Type: EXPERIMENTAL): Participants received erlotinib, 150 milligrams (mg), orally (PO), daily from randomization until progressive disease (PD), death, or unacceptable toxicity.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received a placebo, PO, daily, from randomization until PD, death, or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Patient Anxiety During Radiological Examination

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent~* Age ≥ 18 years~* Scheduled to undergo radiologic imaging evaluation of a tumor~Exclusion Criteria:~* Known hand injury within 30 days prior to study participation~* Known pregnancy~* Mental disability as determined by the treating physician~* Actively receiving radiation therapy~* Actively receiving chemotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- No Massage (Type: NO_INTERVENTION): Subjects in this arm will complete rate their anxiety by visual analog scale (VAS). Blood pressure, pulse and respiration will be recorded before and after imaging. The anxiety VAS will be repeated after the imaging procedure. Subjects in this arm will not receive the hand massage prior to the imaging procedure.
- Hand Massage (Type: EXPERIMENTAL): Subjects in this arm will complete rate their anxiety by visual analog scale (VAS). Blood pressure, pulse and respiration will be recorded before massage, after massage but before imaging, and after imaging.The subjects will receive hand massage prior to the imaging procedure. The anxiety VAS will be repeated after the imaging procedure.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Maverick Total Disc Replacement in a 'Real World' Patient Population

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* Degenerative Disc Disease (DDD) defined as back pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies~* Foraminal stenosis due to loss of disc height~* Back pain and/or leg pain.~Exclusion criteria:~* Spondylolisthesis at the affected or adjacent level~* Posterior facet joint damage and/or disease at the affected level, including facet osteoarthritis, pars fracture and prior laminectomy~* Obesity~* Osteoporosis~* Metallic allergy to cobalt-chromium-molybdenum alloys~* Psychosis~* Infection~* Spinal canal stenosis~* Overlying thoracolumbar kyphosis~* Systemic infection or infection at the site of surgery~* Osteopenia, osteoporosis, or osteomalacia to a degree that spinal instrumentation would be contraindicated~* Diseases of bone metabolism~* Pregnancy~* Signs of local inflammation~* Fever or Leukocytosis~* Grossly distorted anatomy caused by congenital abnormalities~* Any other medical or surgical condition which would preclude the potential benefit of spinal implant surgery, such as the presence of congenital abnormalities, elevation of sedimentation rate unexplained by other diseases, elevation of white blood count (WBC), or a marked left shift in the WBC differential count (this also includes: spinal active oncology pathology; not healed fracture at treated or adjacent level)~* Any case where the implants or components selected would be too large or too small to achieve a successful result~* Any patient in which implant utilization would interfere with anatomical structures or expected physiological performance~* Any patient unwilling to follow postoperative instructions.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- lumbar spinal arthroplasty + Maverick™ (Type: None): Patients requiring total disc replacement

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, ≥18 years of age~* Active rheumatoid arthritis of \>6 months duration~* Received permitted DMARDs each at a stable dose for at least 7 weeks prior to baseline~Exclusion Criteria:~* Rheumatic autoimmune disease or inflammatory joint disease other than rheumatoid arthritis~* Major surgery within 8 weeks prior to screening or planned within 6 months following randomization~* Unsuccessful treatment with a biologic agent, including an anti-TNF agent~* Previous treatment with tocilizumab

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tocilizumab 8 mg/kg + DMARDs (Type: EXPERIMENTAL): None
- Placebo + DMARDs (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: STAT3 DECOY in Head and Neck Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed diagnosis of head and neck squamous cell carcinoma(primary or recurrent) amenable to surgical resection.~* ECOG performance status of 0, 1, or 2.~* Adequate organ function~* Age greater than or equal to 18 years~* Written informed consent.~* Patients with second primary lesions will be eligible for this trial.~* Negative pregnancy test, nonlactating, and using effective means of contraception if childbearing potential.~Exclusion Criteria:~* Subjects who fail to meet the above criteria.~* Subjects who are pregnant.~* Subjects with an ECOG performance status \>2.~* Subjects with tumors that are too small to biopsy prior to resection and reserve a portion of the resected specimen for research purposes.~* Subjects who receive neoadjuvant radiotherapy and/or chemotherapy within four week prior to enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): STAT 3 decoy administration

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Simplifying the Shang Ring Technique for Circumcision of Men and Boys

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 10 years and older;~* Uncircumcised upon clinical examination;~* In good general health;~* Free of genital ulcerations or other visible signs of sexually transmitted infections upon clinical examination;~* Participant and parent or legally acceptable representative (LAR) as applicable must be able to understand study procedures and requirements of study participation;~* Freely consents to participate in the study and signs a written informed consent form if 18 years of age or greater~* Accompanied by the parent/LAR, who freely consents and signs an informed consent form for participation of the child into the study for participants less than 18 years old;~* Assent from participant less than 18 years old who understand study procedure;~* Participant must agree to return to the study site for the full schedule of follow-up visits after his circumcision (or as appropriate the Parent or LAR must agree to bring the participant);~* Participant and parent/LAR as appropriate must agree to provide the study staff with an address, phone number, or other locator information while participating in the research study.~Exclusion Criteria:~* Has a known allergy or sensitivity to lidocaine or other local anesthesia;~* Takes a medication that would be a contraindication for elective surgery, such as an anticoagulant or steroid;~* Has known bleeding/clotting disorder (e.g. hemophilia);~* Has any congenital genitourinary abnormality;~* Has an active genital infection, anatomic abnormality or other condition (e.g. diabetes or sickle cell anemia), which in the opinion of the surgeon, prevents the man from undergoing a circumcision as part of this study; or,~* Is currently participating in another biomedical research study.

- Gender: MALE
- Minimum Age: 10 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Phase 1 - 7 Day Removal (Type: ACTIVE_COMPARATOR): Shang Ring No Flip Technique: Removal of Shang Ring and assessment of healing 7 days after circumcision with no-flip technique.
- Phase 1 - Delayed Removal (Type: ACTIVE_COMPARATOR): Shang Ring No Flip Technique: Removal of ring or assessment of spontaneous detachment at more than 7 days to assess occurrence and safety following circumcision with the no-flip technique.
- Phase 2 - Topical Anesthesia (Type: ACTIVE_COMPARATOR): Comparison of Anesthesia methods for Shang Ring circumcision: Assessment of pain during and after surgery using topical anesthesia.
- Phase 2 - Injectable Anesthesia (Type: ACTIVE_COMPARATOR): Comparison of Anesthesia methods for Shang Ring circumcision: Assessment of pain during and after surgery when using injectable anesthesia.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Participant is a male or female subject 40 years of age or older.~* Participant is willing and able to provide signed and dated written informed consent.~* Participant has a current or past cigarette smoking history (or equivalent for cigar or pipe smoking history) of at least 10 pack-years.~* Participant must be willing and able to attend study visits according to the visit schedule and adhere to all study assessments/procedures.~Exclusion Criteria:~* Participant has a concurrent disease or condition that, in the opinion of the investigator, would interfere with study participation or confound the evaluation of safety, tolerability, or pharmacokinetics of the study drug.~* Participant has a history of reactions or hypersensitivity to inhaled or nebulized anticholinergics, short-acting beta-agonists and long-acting beta-agonists.~* Participant with clinically significant and uncontrolled hypertension, hypercholesterolemia or Type II diabetes mellitus, as assessed by the investigator.~* Participant is unwilling or unable to stop the use of prohibited medications during the washout (if required) and treatment period and follow-up period of the study.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Period 1: Revefenacin + Formoterol (Sequential) (Type: EXPERIMENTAL): Days 1 to 21: Revefenacin and formoterol will be sequentially administered in the morning. Formoterol will be administered again in the evening.
- Period 2: Revefenacin + Formoterol (Combo Solution) (Type: EXPERIMENTAL): Days 22 to 42: After a 21 day period, the participants from the Revefenacin + Formoterol (Sequential) Arm will be dosed for 21 days with a combination of revefenacin and formoterol administered as a combined solution. Formoterol will be administered again in the evening.
- Period 1: Placebo + Formoterol (Sequential) (Type: PLACEBO_COMPARATOR): Days 1 to 21: Placebo versions of revefenacin and formoterol will be sequentially administered in the morning. Formoterol will be administered again in the evening.
- Period 2: Placebo + Formoterol (Combo Solution) (Type: PLACEBO_COMPARATOR): Days 22 to 42: After a 21 day period, the participants from Placebo + Formoterol (Sequential) Arm the will be dosed for 21 days with a combination of placebo revefenacin and formoterol administered as a combined solution. Formoterol will be administered again in the evening.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Adults With Major Depressive Disorder and Anxiety Symptoms

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Main Inclusion Criteria:~* Have a diagnosis of a single or recurrent, nonpsychotic episode of MDD as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) and confirmed by both the Mini International Neuropsychiatric Interview (M.I.N.I.) and an adequate clinical psychiatric evaluation.~* Have a treatment history of an inadequate ADT response to at least 1 ADT (but not \> 3) for the current episode.~* Have received a single, trial-approved, SSRI or SNRI at an adequate dose for~  ≥ 6 weeks prior to screening.~* Are 18 to 65 years old at the time of consent (inclusive, and outpatients only).~* Have a Hamilton Depression Rating Scale (HAM-D)-17-item Total Score ≥ 18 at screening and baseline.~* Have a Hamilton Anxiety Rating Scale (HAM-A) Total Score ≥ 20 at screening and baseline.~Main Exclusion Criteria:~Subjects with any of the following current Axis I DSM-IV-TR diagnoses:~* delirium~* dementia~* amnestic~* other cognitive disorders~* schizophrenia~* schizoaffective disorder~* other psychotic disorders~* bipolar I disorder,~* bipolar II disorder~* bipolar disorder not otherwise specified (NOS)~* eating disorders~* anorexia nervosa~* bulimia~* obsessive compulsive disorder~* post-traumatic stress disorder~Subjects with any of the following current Axis II DSM-IV-TR diagnoses:~* borderline, antisocial~* paranoid~* schizoid~* schizotypal~* histrionic personality disorders~* mental retardation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Brexpiprazole (Type: EXPERIMENTAL): Up to 3 mg/day, once daily dose, tablets, orally

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete